|
1.
|
|
9 p, 1.4 MB |
Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features
/
Font, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Domenech, Montserrat (Althaia Xarxa Assistencial Universitària de Manresa) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Marqués, Miriam (Centro Nacional de Investigaciones Oncológicas) ;
Benítez, Raquel (Centro Nacional de Investigaciones Oncológicas) ;
Ruiz de Porras, Vicenç (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gago, José L. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Carrato, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sant, Francesc (Althaia Xarxa Assistencial Universitària de Manresa) ;
Lopez, Hector (Althaia Xarxa Assistencial Universitària de Manresa) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Malats, Núria (Centro Nacional de Investigaciones Oncológicas) ;
Calle, M. Luz (Universitat de Vic - Universitat Central de Catalunya) ;
Real, Francisco X. (Universitat Pompeu Fabra)
Background and objective: Neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard of care in muscle-invasive bladder cancer (MIBC). Pathological response has been associated with longer survival, but no currently available clinicopathological variables can identify patients likely to respond, highlighting the need for predictive biomarkers. [...]
2023 -  10.3389/fonc.2023.1155244
Frontiers in Oncology, Vol. 13 (august 2023)
|
|
|
2.
|
|
9 p, 1.5 MB |
Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS) : Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups
/
Gronchi, Alessandro (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Hindi, Nadia (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Cruz, Josefina (University Hospital Canarias) ;
Blay, Jean-Yves (Center Leon Berard (Lyon)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Italiano, Antoine (Institute Bergonie - Bourdeaux) ;
Alvarez, Rosa (Hospital General Universitario Gregorio Marañón) ;
Gutierrez, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Rincón, Inmaculada (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sangalli, Claudia (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Pérez Aguiar, José Luis (Hospital Universitario Canarias) ;
Romero, Jesús (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Morosi, Carlo (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Sunyach, Marie Pierre (Center Leon Berard) ;
Sanfilippo, Roberta (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Romagosa, Cleofe (Hospital Universitari Vall d'Hebron) ;
Ranchere-Vince, Dominique (Center Leon Berard) ;
Dei Tos, Angelo (University of Padova) ;
Casali, Paolo G. (University of Milan) ;
Martin-Broto, Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Universitat Autònoma de Barcelona
Myxoid liposarcoma (ML) exhibits a special sensitivity to trabectedin (T) and radiation therapy (RT). Preclinical data suggest a synergistic effect. We aimed to study safety, feasibility and activity of the administration of pre-operative concurrent T and RT in patients affected by localized resectable ML. [...]
2019 - 10.1016/j.eclinm.2019.03.007
EClinicalMedicine, Vol. 9 (march 2019) , p. 35-43
|
|
|
3.
|
|
11 p, 1.2 MB |
Correlation of recist, computed tomography morphological response, and pathological regression in hepatic metastasis secondary to colorectal cancer : The avamet study
/
Vera, Ruth (Instituto de investigaciones Sanitarias de Navarra (IdISNA)) ;
Gómez, María Luisa (Complejo Hospitalario de Navarra) ;
Ayuso Colella, Juan Ramón (Hospital Clínic i Provincial de Barcelona) ;
Figueras, Joan (Hospital Universitari de Girona Doctor Josep Trueta) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Martínez, Virginia (Hospital Universitario La Paz (Madrid)) ;
Lacasta, Adelaida (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Ruiz-casado, Ana (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Safont, María José (Hospital General Universitario de Valencia) ;
Aparicio Urtasun, Jorge (Hospital Universitari i Politècnic La Fe (València)) ;
Campos, Juan Manuel (Hospital Arnau de Vilanova (València)) ;
Cámara, Juan Carlos (Hospital Universitario Fundación Alcorcón) ;
Martín-Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Montagut Viladot, Clara (Hospital del Mar (Barcelona, Catalunya)) ;
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Vieitez, Jose María (Hospital Universitario Central de Asturias) ;
Falcó, Esther (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Jorge, Mónica (Hospital Xeral Cíes) ;
Marín, Miguel (Hospital Clínico Universitario de la Arrixaca) ;
Salgado, Mercedes (Complejo Hospitalario de Ourense) ;
Viúdez, Antonio (Instituto de investigaciones Sanitarias de Navarra (IdISNA)) ;
Universitat Autònoma de Barcelona
The prospective phase IV AVAMET study was undertaken to correlate response evaluation criteria in solid tumors (RECIST)-defined response rates with computed tomography-based morphological criteria (CTMC) and pathological response after liver resection of colorectal cancer metastases. [...]
2020 - 10.3390/cancers12082259
Cancers, Vol. 12 Núm. 8 (august 2020) , p. 1-12
|
|
|
4.
|
|
18 p, 3.7 MB |
Neoadjuvant Chemotherapy plus Interval Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (NIHIPEC) in the Treatment of Advanced Ovarian Cancer : A Multicentric Propensity Score Study
/
Llueca, Antoni (Department of Medicine, University Jaume I) ;
Ibañez, Maria Victoria (Department of Mathematics, University Jaume I) ;
Cascales, Pedro (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Gil-Moreno, Antonio 1965- (Vall d'Hebron Institut d'Oncologia) ;
Bebia, Vicente (Vall d'Hebron Institut d'Oncologia) ;
Ponce, Jordi (Department of Gynecology, University Hospital of Bellvitge) ;
Fernández-González, Sergi (Department of Gynecology, University Hospital of Bellvitge, 08907 Barcelona, Spain; (J.P.); (S.F.)) ;
Arjona-Sanchez, Alvaro (University Hospital Reina Sofia) ;
Muruzabal, Juan Carlos (Department of Gynecologic Oncology, Complejo Hospitalario de Navarra) ;
Veiga, Nadia (Department of Gynecologic Oncology, Complejo Hospitalario de Navarra) ;
Díaz-Feijoo, Berta (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Celada, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gilabert-Estelles, Juan (Department of Obstetrics and Gynecology, University General Hospital of Valencia) ;
Aghababyan, Cristina (Department of Obstetrics and Gynecology, University General Hospital of Valencia) ;
Lacueva, Javier (Department of General Surgery, University General Hospital of Elche) ;
Calero, Alicia (Department of General Surgery, University General Hospital of Elche) ;
Segura-Sampedro, Juan José (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Maiocchi, Karina (Department of General Surgery, University General Hospital of Castellon) ;
Llorca, Sara (Department of General Surgery, University General Hospital of Castellon) ;
Villarin, Alvaro (Department of General Surgery, University General Hospital of Castellon) ;
Climent, Maria Teresa (Department of Medicine, University Jaume I) ;
Delgado, Katty (Department of Medicine, University Jaume I) ;
Serra Rubert, Anna (Department of Medicine, University Jaume I) ;
Gomez-Quiles, Luis (Department of General Surgery, University General Hospital of Castellon) ;
Llueca, Maria (Hospital Universitari Joan XXIII de Tarragona) ;
Universitat Autònoma de Barcelona
Advanced ovarian cancer (Stages III-IV) continues to be one of the gynecological tumors with the highest mortality. Standard treatment consists of debulking surgery and subsequent adjuvant chemotherapy. [...]
2023 - 10.3390/cancers15174271
Cancers, Vol. 15 (august 2023)
|
|
|
5.
|
|
14 p, 2.0 MB |
Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer
/
Angeles, Martina Aida (Institut Universitaire du Cancer de Toulouse Oncopole) ;
Cabarrou, Bastien (Institut Universitaire du Cancer de Toulouse Oncopole) ;
Gil-Moreno, Antonio 1965- (Vall d'Hebron Institut d'Oncologia) ;
Pérez-Benavente, Assumpció (Vall d'Hebron Institut d'Oncologia) ;
Spagnolo, Emanuela (Hospital Universitario La Paz (Madrid)) ;
Rychlik, Agnieszka (Department of Gynaecologic Oncology, Maria Skłodowska-Curie National Research Institute of Oncology) ;
Martínez-Gómez, Carlos (INSERM CRCT 1 (França)) ;
Guyon, Frédéric (Department of Surgical Oncology, Institut Bergonié (França)) ;
Zapardiel, Ignacio (Hospital Universitario La Paz (Madrid)) ;
Querleu, Denis (Honorary Professor of the University of Toulouse) ;
Illac, Claire (Institut Universitaire du Cancer de Toulouse Oncopole) ;
Migliorelli, Federico (Department of Gynaecology and Obstetrics, Centre Hospitalier Intercommunal des Vallées de l'Ariège (França)) ;
Bétrian, Sarah (Institut Universitaire du Cancer de Toulouse Oncopole) ;
Ferron, Gwénaël (INSERM CRCT 19 (França)) ;
Hernández Gutierrez, Alicia (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Martinez, Alejandra (INSERM CRCT 19 (França)) ;
Universitat Autònoma de Barcelona
We sought to evaluate the impact on survival of tumor burden and surgical complexity in relation to the number of cycles of neoadjuvant chemotherapy (NACT) in patients with advanced ovarian cancer (OC) with minimal (CC-1) or no residual disease (CC-0). [...]
2021 - 10.3802/jgo.2021.32.e78
Journal of Gynecologic Oncology, Vol. 32 (august 2021)
|
|
|
6.
|
|
14 p, 486.2 KB |
Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy
/
Virgili Manrique, Anna Cristina (Institut d'Investigació Biomèdica Sant Pau) ;
Salazar, Juliana (Institut d'Investigació Biomèdica Sant Pau) ;
Arranz, María Jesús (Fundació Docència i Recerca Mútua Terrassa) ;
Bagué Rosell, Sílvia (Institut d'Investigació Biomèdica Sant Pau) ;
Orellana-Fernández, Ruth (Institut d'Investigació Biomèdica Sant Pau) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Cerdà, Paula (Institut d'Investigació Biomèdica Sant Pau) ;
Gracia, Isidre (Institut d'Investigació Biomèdica Sant Pau) ;
Majercakova, Katarina (Institut d'Investigació Biomèdica Sant Pau) ;
Peiró, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Trullols, L. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Fernández Garrido, Manuel (Institut d'Investigació Biomèdica Sant Pau) ;
Valverde, Sandra (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Quintana Ruiz, Maria Jesús (Institut d'Investigació Biomèdica Sant Pau) ;
Bell, Olga (Institut d'Investigació Biomèdica Sant Pau) ;
Artigas-Baleri, Alícia (Institut d'Investigació Biomèdica Sant Pau) ;
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Neoadjuvant chemotherapy based on anthracyclines and ifosfamide for high-risk soft tissue sarcomas (STS) of the extremities and trunk is a controversial treatment option. There are sub-stantial interindividual differences in clinical outcomes in patients treated with neoadjuvant chem-otherapy. [...]
2022 - 10.3390/jpm12040618
Journal of personalized medicine, Vol. 12 Núm. 4 (april 2022) , p. 618
|
|
|
7.
|
|
12 p, 815.7 KB |
Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response
/
Ciriaco, Nikaoly (Hospital del Mar (Barcelona, Catalunya)) ;
Zamora, Esther (Hospital Universitari Vall d'Hebron) ;
Escrivá-de-Romaní, Santiago (Hospital Universitari Vall d'Hebron) ;
Miranda Gómez, Ignacio (Hospital Universitari Vall d'Hebron) ;
Jiménez Flores, José (Vall d'Hebron Institut d'Oncologia) ;
Saura, Cristina (Hospital Universitari Vall d'Hebron) ;
Sloane, Hillary ;
Starus, Anna ;
Fredebohm, Johannes ;
Georgieva, Lucy ;
Speight, Graham ;
Jones, Frederick ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron) ;
Espinosa-Bravo, Martín (Hospital Universitari Vall d'Hebron) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Although the standard of care is to perform surgery of primary breast cancer (BC) after neoadjuvant chemotherapy (NAC), for certain patients achieving clinical complete response (cCR) and pathologic complete response (pCR), omission of surgical treatment may be an option. [...]
2022 - 10.1177/17588359221139601
Therapeutic Advances in Medical Oncology, Vol. 14 (november 2022)
|
|
|
8.
|
|
12 p, 976.6 KB |
SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)
/
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Gómez, M.A. (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Guillot, M. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Pericay, C. (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Safont, M.J. (Consorcio Hospital General Universitario de Valencia. Universidad de Valencia. CIBERONC) ;
Tarazona, N. (Centro de Investigación Biomédica en Red de Cáncer) ;
Vera, R. (DHospital Universitario de Navarra; Navarrabiomed. IDISNA) ;
Vidal, J. (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Sastre Valera, Javier (Hospital Universitario Clínico San Carlos (Madrid))
The management of localized rectal cancer requires a multidisciplinary approach to optimize outcomes, reduce morbidity and prevent under or overtreatments. While early stages may obtain benefit of local resections without any additional therapies, locally advanced rectal cancer becomes a challenge defining the better sequential strategy of surgery, radiotherapy and chemotherapy. [...]
2022 - 10.1007/s12094-022-02816-9
Clinical & Translational Oncology, Vol. 24 Núm. 4 (april 2022) , p. 646-657
|
|
|
9.
|
|
10 p, 2.5 MB |
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
/
Gil-Gil, M.J. (Institut Català d'Oncologia) ;
Bellet Ezquerra, Meritxell (Hospital Universitari Vall d'Hebron) ;
Bergamino, M. (Institut Català d'Oncologia) ;
Morales, S. (Hospital Arnau de Vilanova (València)) ;
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Manso, Luis (Hospital Universitario 12 de Octubre (Madrid)) ;
Saura, Cristina (Hospital Universitari Vall d'Hebron) ;
Fernández-Ortega, A. (Institut Català d'Oncologia) ;
Garcia-Martinez, E. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Martinez-Jañez, N. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Melé, M. (Hospital Sant Joan) ;
Villagrasa, P. (SOLTI Breast Cancer Research Group) ;
Céliz, Pamela (SOLTI Breast Cancer Research Group) ;
Perez Martin, X. (Institut Català d'Oncologia. L'Hospitalet) ;
Ciruelos, Eva (Department of Medical Oncology. Hospital) ;
Pernas, S. (Institut Català d'Oncologia)
Background: The CAPRICE trial was designed to specifically evaluate neoadjuvant pegylated liposomal doxorubicin (PLD) in elderly patients or in those with other cardiovascular risk factors in whom conventional doxorubicin was contraindicated. [...]
2021 - 10.3389/fonc.2021.645026
Frontiers in Oncology, Vol. 11 (september 2021) , p. 645026
|
|
|
10.
|
|
9 p, 747.5 KB |
Predictive and prognostic value of total tumor load in sentinel lymph nodes in breast cancer patients after neoadjuvant treatment using one-step nucleic acid amplification : the NEOVATTL study
/
Vieites, B. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
López-García, M. (Centro de Investigación Biomédica en Red de Cáncer) ;
Martín-Salvago, M.D. (Hospital Universitario Materno-Infantil) ;
Ramirez-Tortosa, C.L. (Hospital Universitario Materno-Infantil) ;
Rezola, R. (Onkologikoa Kutxa Fundazioa) ;
Sancho, M. (Hospital Universitario de Salamanca) ;
López Vilaró, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Villardell, F. (Hospital Universitario Arnau de Vilanova) ;
Burgués, Octavio (Hospital Clínic Universitari (València)) ;
Fernández-Rodriguez, B. (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Alfaro, L. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Peg, Vicente (Centro de Investigación Biomédica en Red de Cáncer)
Objective: To evaluate the predictive and prognostic value of total tumor load (TTL) in sentinel lymph nodes (SLNs) in patients with infiltrating breast cancer after neoadjuvant systemic therapy (NST). [...]
2021 - 10.1007/s12094-020-02530-4
Clinical & Translational Oncology, Vol. 23 Núm. 7 (july 2021) , p. 1377-1385
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
